NEWS DETAIL

  • Source : PR Newswire
  • Date : 2020-11-19
  • Event type : Phase 1,Phase 2
  • Companies : Roche

SynOx Secured Exclusive World-Wide Rights for the Clinical Development, Manufacturing and Commercialization of Emactuzumab Under a Licence Agreement with Roche

DUBLIN, Nov. 19, 2020 /PRNewswire/ -- SynOx Therapeutics Ltd , a spin out of Celleron Therapeutics Ltd (“Celleron”), secured exclusive world-wide rights for the clinical development, manufacturing and commercialization of emactuzumab under a licence agreement with Roche for the treatment of diffuse tenosynovial giant cell tumours (“TGCT”), also known as pigmented villonodular synovitis (”PVNS”), and other indications.

Emactuzumab is a clinical-stage humanised IgG1 CSF-1R targeted antibody designed to target and deplete macrophages in the tumour tissue. It has shown a favourable safety profile in patients and encouraging efficacy for TGCT, a rare disease characterised by the proliferation of macrophages in the synovial tissue in the joint and tendon sheath.

Professor Nick La Thangue, Chief Executive Officer of SynOx, commented: "We are very excited to be developing emactuzumab as a breakthrough treatment for the extreme and debilitating effects of TGCT. SynOx will be focused on generating all necessary data to register this new therapy in a time- and cost-efficient way."

About SynOx Therapeutics

SynOx is a clinical stage biopharmaceutical company. It is a spin out from Celleron Therapeutics Ltd, an oncology company focused on the clinical development of new and innovative therapies to treat cancer. SynOx is developing emactuzumab, a best-in-class CSF1R targeted therapeutic antibody designed to target and deplete tumour-associated macrophages in the tumour tissue. SynOx is led by a team of experts that combines biotech and pharma experience with a successful track record of developing and bringing products to market. It is backed by a strong investor syndicate – HealthCap, Medicxi, Forbion and Gimv.

Please visit us at: https://synoxtherapeutics.com/ and on Twitter: @SynOx_Tx

A paper on emactuzumab was published in the European Journal of Cancer, Volume 141, December 2020 edition, Long-term clinical activity, safety and patient-reported quality of life for emactuzumab-treated patients with diffuse-type tenosynovial giant-cell tumour

https://www.ejcancer.com/article/S0959-8049(20)31046-7/abstract


Reference News > https://www.pharmacircle.com/one_news.php?id=545908